Drug intelligence / Profile preview

amiprilose

Development stage
Discontinued
Lead developer
Alseres Pharmaceuticals
Modality
Small Molecules
Administration
Oral
01

Overview

Amiprilose is a synthetic carbohydrate derivative, specifically a substituted D-glucofuranose, that possesses immunomodulatory and anti-inflammatory properties. Developed primarily for the treatment of rheumatoid arthritis, it functions by modulating the production of pro-inflammatory cytokines such as interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF-alpha), and by inhibiting the proliferation of synovial fibroblasts. Although it demonstrated a favorable safety profile and some efficacy in early clinical trials as a disease-modifying antirheumatic drug (DMARD), its development was ultimately discontinued after failing to meet primary endpoints in pivotal Phase 3 studies and receiving a non-approvable letter from the FDA in the early 1990s.

Brand names
Therafectin
Other names
amiprilose hydrochlorideamiprilose HCl1,2-O-isopropylidene-3-O-3'-(N',N'-dimethylamino-n-propyl)-D-glucofuranose
02

Targets

TNFA (Tumor necrosis factor alpha (soluble))IL1A (Interleukin 1 alpha)

Beyond the preview

Go deeper on amiprilose.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on amiprilose.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call